Notably, ZDHHC17-promoted activation of JNK/p38 was PAT-independent, and ZDHHC17-expressing glioma cell malignancy characteristics were not suppressed by the PAT inhibitor, 2-bromopalmitate (2BP). Here, MAPK1 is linked to central nervous system cancer.